Cytovia Therapeutics’ Scientific Leadership to Present at Upcoming Conferences

AVENTURA, Fla. & NATICK, Mass.--(BUSINESS WIRE)-- Cytovia Therapeutics, a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK cells (NK cells derived from induced pluripotent stem cells, or iPSCs), CAR (Chimeric Antigen Receptor)-iNK cells, and Flex-NK™ cell engager multifunctional antibodies, announced today that its scientific leadership will present at the following upcoming conferences:

iPSC-Derived Cell Therapies Summit (Virtual Event)

Wednesday, December 8th, 2021, 9.30 AM
Demonstrating Safety & Efficacy of iPSC-derived Cells to Maximize Clinical Translation
(Industry Leaders’ Fireside Chat: Paving the Way For the Future of Cell Therapy with iPSCs)
Featuring Cytovia Therapeutics CMO Stanley Frankel

Wednesday, December 8th, 2021, 3PM
Advancing Clinical Trial Strategy for Successful Clinical Outcomes
(Developing iPSC-Derived NK Cell Therapies Against Solid Tumors)
Featuring Cytovia Therapeutics CSO Wei Li

Antibody Engineering & Therapeutics Conference (San Diego, California)

December 12^th-15^th, 2021
Dr. Jean Kadouche, Cytovia Therapeutics scientific co-founder and Global Head of Antibody R&D, will present the “Design, Manufacturing, and Activity of FLEX Immune Cell Engager Multi-functional Antibodies” poster on behalf of the Cytovia team.

“We are proud of the scientific thought leadership of our colleagues Drs. Frankel, Li, and Kadouche, who will present Cytovia’s latest advances,” said Dr. Daniel Teper, CEO of Cytovia Therapeutics. “Cytovia is committed to translating disruptive innovation in cell therapy to create therapeutics that advance towards a cancer cure. Cytovia is the first biotech company to develop its own best-in-class gene-edited, iPSC-derived NK cells and NK Engager antibodies, with the potential to combine them for optimal clinical outcomes in both hematological and solid tumors.”

About Cytovia Therapeutics

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. It is developing three types of iPSC-derived (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using its proprietary Flex-NK™ technology.

These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as refractory multiple myeloma.

Cytovia’s research and development laboratories in Natick, MA and GMP cell manufacturing facility in Puerto Rico are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, and the University of California San Francisco (UCSF).

Cytovia Therapeutics has recently formed CytoLynx Therapeutics, a joint-venture entity focused on research and development, manufacturing, and commercialization activities in Greater China and beyond.

Find out more at www.cytoviatx.com and follow us on Facebook, Twitter, LinkedIn, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005575/en/